Endocrine
12Pituitary, thyroid and indirect testosterone claims.
Hormonal
Testagen
KEDG tetrapeptide
Community reportsHormone support2
No FDA-approved product identified for this exact research entry in the targeted review.
What does it do?
A KEDG bioregulator promoted for pituitary/thyroid support, without established human clinical benefit.
Approved & studied uses
No established medical use is documented for this formulation.
Evidence limits
View research →An exact-compound controlled human endocrine trial was not verified.1
1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Evidence limitation
Corrosion experiments do not assess human toxicity.1
No FDA-approved product identified for this exact research entry in the targeted review.
Amino-acid sequence
- Lys
- Glu
- Asp
- Gly
4 residues · N → C1
Reference identity · not independently confirmed12
Length4 amino acids
Molecular weight · Da447.4 Da
Formula, sequence notation & identity
K–E–D–GLys-Glu-Asp-Gly (KEDG)
Exact sequence identified in the materials paper; unspecified salts and research products are not interchangeable.
Pep-Pedia identity details
4 amino acids · 447.4 Da
H-Lys-Glu-Asp-Gly-OH (KEDG)Reference description; checked chemical identity above takes precedence when available.12
Pharmacokinetics
How long does it stay in the body?
Unverified reference estimateNot independently confirmed
Reference half-life30 min11
Route / formulationSource page: Injectable. Exact PK route not verified.
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 2.5 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Khavinson et al.
Source’s reported peak time: 15 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Unverified reference estimateNot independently confirmed
Reference half-life1 hr11
Route / formulationSource page: Oral. Exact PK route not verified.
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 5 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Khavinson et al.
Source’s reported peak time: 30 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Recent exact-compound paper is a materials study
An exact-compound controlled human endocrine trial was not verified.1
Reported timelines
Reference & communitySource expectations
Injection: minimal 1–2 weeks, energy/mood 3–4, thyroid/metabolic claims 5–8, hormonal claims 8–12. Oral changes claimed from 2–4+ weeks; unvalidated.12
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Effectiveness
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “36 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Not testosterone replacement. Short peptide size does not establish oral efficacy; source pairing labels do not establish safety.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQ | 100 mcgStarting dose | Once daily | Starting / Titration (Weeks 1-2)Reference report | 8-12 weeks | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Not testosterone replacement. Short peptide size does not establish oral efficacy; source pairing labels do not establish safety. Source tabs Injectable | |||||
| SubQ | 150 mcg | Once daily | Building (Weeks 3-4)Reference report | 8-12 weeks | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Not testosterone replacement. Short peptide size does not establish oral efficacy; source pairing labels do not establish safety. Source tabs Injectable | |||||
| SubQ | 200 mcg | Once daily | Standard (Weeks 5-8)Reference report | 8-12 weeks | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Not testosterone replacement. Short peptide size does not establish oral efficacy; source pairing labels do not establish safety. Source tabs Injectable | |||||
| SubQ | 250-300 mcg | Once daily | Maximum (Weeks 9-12)Reference report | 8-12 weeks | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Not testosterone replacement. Short peptide size does not establish oral efficacy; source pairing labels do not establish safety. Source tabs Injectable | |||||
| Oral | 1-2 capsules | 1-2x daily with meals | Standard supplementationReference report | 20+ days minimum | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Not testosterone replacement. Short peptide size does not establish oral efficacy; source pairing labels do not establish safety. Source tabs Oral | |||||
| Oral | 1-2 capsules daily | For at least 20 days | Minimum courseReference report | 20+ days minimum | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Not testosterone replacement. Short peptide size does not establish oral efficacy; source pairing labels do not establish safety. Source tabs Oral | |||||
| Oral | 1-2 capsules daily | After 4-6 month break | Repeat courseReference report | 20+ days minimum | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Not testosterone replacement. Short peptide size does not establish oral efficacy; source pairing labels do not establish safety. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 8-12 weeks
- Break
- 4-6 months between cycles
Reported timing
Morning preferred for circadian alignment
Oral
- Use period
- 20+ days minimum
- Break
- 4-6 months between courses
Reported timing
With meals for optimal absorption
Side effects & safety
Evidence limitation
Corrosion experiments do not assess human toxicity.
1Evidence limitation
No validated human interaction or exposure data were identified in the checked exact-compound source.
1Unknown safety
No verified human trials; thyroid cancer/hyperthyroidism are source cautions. Pregnancy/breastfeeding safety unknown.
Stop symptoms
Tachycardia, tremor, heat intolerance, unexplained weight loss, neck swelling, anxiety, allergy, severe local reactions or persistent GI upset.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
CJC-1295
Caution reportedEndocrine overlap.12
Reference report · Pep-Pedia label: Monitor CombinationThyroid medicines
Caution reportedPossible thyroid changes.12
Reference report · Evidence context: Monitor combinationTRT / testosterone
Caution reportedHormone assessment needed.12
Reference report · Pep-Pedia label: Monitor CombinationEpitalon
Unverified pairingUnproven bioregulator pairing.12
Reference report · Pep-Pedia label: SynergisticPinealon
Unverified pairingUnproven pairing.12
Reference report · Pep-Pedia label: SynergisticThymalin
Unverified pairingUntested pairing.12
Reference report · Pep-Pedia label: CompatibleIpamorelin
Unverified pairingUntested pairing.12
Reference report · Pep-Pedia label: CompatibleBPC-157
Unverified pairingUntested pairing.12
Reference report · Pep-Pedia label: CompatibleOther medicines or peptides
Not establishedNo exact-product human interaction study was verified; lack of evidence is not evidence of safety.2
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
The cited saline preparation was used for corrosion testing, not injection.1
Formulation boundary
A materials experiment cannot establish injectable diluent compatibility, sterility or storage.1
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The source gives an example for a 20 mg vial.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- 20 mg in 3 mL gives approximately 6.67 mg/mL, or 66.7 mcg per U-100 unit. · Reported example volumes: 100/200/300 mcg correspond to 1.5/3/4.5 U-100 units. · Reported storage: 2–8°C.
The source describes gentle mixing and avoiding vigorous shaking.
Fractional-unit volumes require a device that can actually measure them; the example is not a dose recommendation.
Oral
The source describes capsules taken with meals.
- Form
- Source describes a prepared product
- Reported parameters
- Reported course: at least 20 days; reported break: 4–6 months. · Storage: original container at room temperature.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite Lyophilized PowderReported appearanceClear Reconstituted SolutionReported appearanceVerified Source with COAReported variationLimited Research BaseReported concernDiscoloration or ParticlesReported concernUnknown Source
12Vial sizes
20mg1
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.12
Full storage notes from Pep-Pedia
12Lyophilized -20°C, Reconstituted 2-8°C
Room temperature
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements Scales, capacity & references
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Research findings
No human data verifiedSource context
Not testosterone replacement. Short peptide size does not establish oral efficacy; source pairing labels do not establish safety.
Compound identity & other names
Testagen is the Lys-Glu-Asp-Gly tetrapeptide. The located literature does not establish testosterone restoration or fertility benefits in people. Testagen TDS is an unrelated testosterone product.
No FDA-approved product identified for this exact research entry in the targeted review.
How it may work
Proposed gene-regulatory effects on TSH; indirect testosterone effects remain hypotheses.12
Recent exact-compound paper is a materials study
A 2025 paper tested KEDG/Testagen for copper corrosion inhibition. It provides chemical and laboratory-supply information, not evidence that Testagen raises testosterone or treats endocrine disease.
1Research areas and evidence gaps
- An exact-compound controlled human endocrine trial was not verified.
Community reports Unvalidated
Pep-Pedia discusses hormonal support interest.2
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
The verified 2025 exact-compound paper concerns copper corrosion, not endocrine efficacy. No controlled human KEDG trial was verified.
- Checked
- 2026-10-12
- Search
- "Testagen" peptide study 2025 2026
- Catalog
- Pep-Pedia ↗ · 8 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1The Inhibitory Effect and Adsorption Properties of Testagen Peptide on Copper Surfaces in Saline Environments: An Experimental and Computational StudyPrimary source checked
AI-PREPARED SUMMARY
The KEDG tetrapeptide was tested for copper corrosion inhibition in saline. This materials-science experiment does not establish a testosterone, thyroid or clinical benefit.
Recent exact-compound paper is a materials study
A 2025 paper tested KEDG/Testagen for copper corrosion inhibition. It provides chemical and laboratory-supply information, not evidence that Testagen raises testosterone or treats endocrine disease.
Additional research · Checked 2026-10-12
2Pep-Pedia: TestagenCommunity source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
3Hypophysectomized Avian Model StudyNo study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source describes thyroid morphology and body-weight changes in pituitary-removed birds; this is not human testosterone evidence.
Reported population / model
Avian model
Reported study details
Pituitary-removed birds · Thyroid gland morphology assessment
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4Thyroid Function Without Hypophyseal SupportNo study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source invokes pituitary stimulation despite absent pituitary support, an internal mechanistic contradiction that remains unresolved.
Reported population / model
Preclinical
Reported study details
TSH and thyroid hormone modulation · Gene expression analysis
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Peptide Bioregulator Thyroid Correction Study (2005)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The human thyroid report concerns Thyramin, a different bioregulator; it does not establish Testagen efficacy.
Reported population / model
Humans
Reported study details
Magadan Region · Elderly with hypothyroidism · Thyramin bioregulator
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Khavinson Peptide Gene Expression StudyNo study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Short-peptide DNA/histone interactions are described in laboratory work; a class mechanism cannot establish effects of this specific product.
Reported population / model
In vitro
Reported study details
Short peptides · DNA and histone interaction analysis
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Testosterone and Thyroid Hormone CorrelationNo study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Thyroid replacement can affect testosterone in hypothyroidism; that relationship is not a clinical test of Testagen.
Reported population / model
Research review
Reported study details
Hypothyroidism and testosterone relationship
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Peptide bioregulators: A new class of geroprotectorsLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
9Peptide bioregulator efficacy in correcting reduced thyroid function in Magadan residentsPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The human thyroid report concerns Thyramin, a different bioregulator; it does not establish Testagen efficacy.
Reported population / model
Humans
Reported study details
Magadan Region · Elderly with hypothyroidism · Thyramin bioregulator
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Peptide Regulation of Gene Expression: A Systematic ReviewLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
11Pep-Pedia: Testagen — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 30 min and a peak time of 15 min. Stated attribution: Khavinson et al.. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
12Pep-Pedia: Testagen — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12